Relmada Therapeutics wins first European patent for SECUREL technology and lead pain therapy product candidate LevoCap ER.
M2 EQUITYBITES-July 7, 2016-Relmada Therapeutics wins first European patent for SECUREL technology and lead pain therapy product candidate LevoCap ER
(C)2016 M2 COMMUNICATIONS http://www.m2.com
Novel therapies company Relmada Therapeutics (Other OTC:RLMD) reported on Wednesday that it has been granted a patent (EP 2 448 406 B1) from the European Patent Office (EPO) for compositions and methods of use for its extended release oral levorphanol (3-hydroxy-N-methylmorphinan).
The patent is titled "Extended Release Oral Pharmaceutical Compositions of 3-hydroxy-N-methylmorphinan" and broadly covers the company's SECUREL technology platform and LevoCap ER (REL-1015, levorphanol extended-release, abuse deterrent capsules).
According to the company, the patent is not scheduled to expire until 2030.
LevoCap ER is an extended release, abuse resistant form of levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other strong opioids. It is being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
SECUREL is an proprietary abuse deterrent extended release technology for opioid drugs. Its dosage forms cannot be easily crushed for inhalation or to obtain rapid euphoria from high blood levels when swallowed. It is exceedingly difficult for IV abusers to extract the active drug from the dosage form using common solvents, including alcohol, concluded the company.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jul 7, 2016|
|Previous Article:||Alexandria Real Estate Equities commences public offering of 6.5m common stock.|
|Next Article:||CBS prices offering of USD700m senior notes due 2027.|